CA-074: Selective Cathepsin B Inhibitor for Cancer Metastasis and Neurotoxicity Research

Executive Summary: CA-074 is a small molecule inhibitor with high selectivity for cathepsin B (Ki = 2–5 nM), showing >10,000-fold selectivity over cathepsins H and L, and is widely used in cancer metastasis and neurotoxicity research (ApexBio). Chemical inhibition of cathepsin B protects cells from necroptosis, as demonstrated in MLKL-mediated lysosomal disruption models (Liu et al., 2024). CA-074 reduces bone metastasis in 4T1.2 breast cancer mouse models and suppresses Abeta42-induced neurotoxicity in microglial systems (see review). The compound exhibits minimal cytotoxicity at 10 mM in cell culture and is suitable for in vivo use via intraperitoneal injection at 50 mg/kg. CA-074's high solubility in DMSO, ethanol, and water facilitates diverse experimental designs.

Biological Rationale

Cathepsin B is a lysosomal cysteine protease involved in proteolytic remodeling during cancer metastasis, inflammation, and neuronal injury (Liu et al., 2024). In necroptosis, MLKL polymerization triggers lysosomal membrane permeabilization (LMP), causing the release of cathepsin B into the cytosol, which then cleaves essential cell survival proteins. Dysregulated cathepsin B activity exacerbates disease progression in cancer and neurodegenerative disorders. Selective inhibition allows researchers to dissect the functional contribution of cathepsin B versus other cathepsins, which is crucial for mechanistic studies and therapeutic development. CA-074 offers a targeted approach to modulate these proteolytic cascades without broad-spectrum lysosomal disruption (ApexBio).

Mechanism of Action of CA-074, Cathepsin B inhibitor

CA-074 is a peptide-derived small molecule with a molecular weight of 383.44 g/mol and the chemical name (2S)-1-[(2S,3S)-3-methyl-2-[[(3S)-3-(propylcarbamoyl)oxirane-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carboxylic acid (ApexBio). It binds the active site of cathepsin B, forming a reversible, non-covalent complex that blocks substrate access. The inhibition constant (Ki) is 2–5 nM for cathepsin B, with Ki values for cathepsins H and L exceeding 40–200 µM, indicating high selectivity (CA-074 review). By inhibiting cathepsin B, CA-074 interrupts the proteolytic activation of downstream effectors in cancer cell invasion, immune response skewing, and neuronal injury. In necroptosis models, CA-074 suppresses MLKL-induced cell death by preventing cathepsin B–mediated proteolysis following lysosomal disruption (Liu et al., 2024).

Evidence & Benchmarks

• CA-074 exhibits nanomolar inhibition of cathepsin B (Ki = 2–5 nM at pH 5.5–6.0); Ki for cathepsins H and L are 40–200 µM, confirming >10,000-fold selectivity (ApexBio).
• In 4T1.2 breast cancer mouse models, CA-074 (50 mg/kg, i.p.) reduces bone metastasis without affecting primary tumor growth (review).
• Inhibition of cathepsin B with CA-074 protects human colon cancer HT-29 cells from necroptosis in MLKL polymerization-induced lysosomal membrane permeabilization assays (Liu et al., 2024).
• CA-074 suppresses Abeta42-activated microglial neurotoxicity, reducing neuronal cell death in co-culture models (mechanistic insights).
• At 10 mM in cell culture, CA-074 shows negligible cytotoxicity in standard viability assays (ApexBio).
• Solubility parameters: >19.17 mg/mL (DMSO), >31.3 mg/mL (ethanol), >5.91 mg/mL (water, ultrasonic aid) (ApexBio).

Applications, Limits & Misconceptions

CA-074 is primarily applied in mechanistic studies of cancer metastasis, neurotoxicity, necroptosis, and immune modulation. It is suitable for both in vitro and in vivo models due to high selectivity and solubility. For example, it enables the study of cathepsin B–mediated proteolytic cascades without off-target effects on cathepsins H and L. In immune research, CA-074 has been shown to shift helper T cell responses from Th-2 to Th-1 profiles, reducing IgE and IgG1 levels (immune modulation).

This article extends the discussion in CA-074: Selective Cathepsin B Inhibitor for Cancer Metast... by integrating recent necroptosis findings and clarifying dosage parameters. It also updates CA-074: Next-Generation Cathepsin B Inhibition for Advanc... by specifying solubility and cytotoxicity thresholds for diverse workflows.

Common Pitfalls or Misconceptions

• CA-074 is highly selective for cathepsin B but does not inhibit cathepsins H or L at concentrations used in standard protocols; it is not a pan-cathepsin inhibitor.
• CA-074 is not effective against cathepsin B in non-acidic environments; optimal activity is observed at lysosomal (acidic) pH (~5.5).
• CA-074 should not be used for long-term storage in solution; short-term (hours to days) use is recommended at -20°C.
• It does not directly inhibit MLKL or block necroptosis unless cathepsin B is the major executioner protease in the pathway.
• High concentrations above tested thresholds (>10 mM in vitro, >50 mg/kg in vivo) may lead to off-target effects not documented in current literature.

Workflow Integration & Parameters

CA-074 (ApexBio SKU: A1926, product page) is provided as a lyophilized powder or solution. Dissolve in DMSO (>19.17 mg/mL), ethanol (>31.3 mg/mL), or water (>5.91 mg/mL with ultrasonic assistance). For in vitro assays, working concentrations typically range from 10 nM to 100 µM, with negligible cytotoxicity up to 10 mM. In vivo, 50 mg/kg via intraperitoneal injection is effective for metastasis models. Storage at -20°C is advised; solutions are for short-term use only. CA-074 is compatible with cell viability, apoptosis, migration, and immunological assays. When integrating into necroptosis studies, ensure treatment coincides with or precedes the induction of MLKL polymerization or lysosomal stress (Liu et al., 2024).

Conclusion & Outlook

CA-074 is a gold-standard tool for selective cathepsin B inhibition in cancer metastasis, neurotoxicity, immune modulation, and necroptosis research. Its robust performance, high specificity, and established benchmarks make it essential for dissecting cathepsin B–mediated proteolytic and immune pathways. Future developments may extend its utility in translational settings and drug development, especially as new roles for cathepsin B in cell death and immune regulation are elucidated. For more advanced translational insights, see CA-074: Advancing Cathepsin B Inhibition in Necroptosis a..., which this article updates by integrating recent mechanistic evidence for MLKL–cathepsin B axis in necroptosis.